imc@healthandcommerce.com, Author at Corcept Therapeutics - Page 2 of 16

About imc@healthandcommerce.com

This author has not written his bio yet.
But we are proud to say that imc@healthandcommerce.com contributed 159 entries already.

Entries by imc@healthandcommerce.com

The Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension

Plutzky et al. • 2025 • Heart in Diabetes 2025

June 9, 2025

High Medication and Cardiovascular Disease Burden in Individuals With Difficult-to-Control Type 2 Diabetes: Clinical Characteristics From the CATALYST Study

DeFronzo et al. • 2025 • Heart in Diabetes 2025

June 9, 2025

DAZALS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Of Dazucorilant, A Selective Glucocorticoid Receptor Modulator, In Amyotrophic Lateral Sclerosis

van den Berg et al. • 2025 • ENCALS 2025 Congress

June 5, 2025

ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer

A. Olawaiye et al. • 2025 •

June 2, 2025

Efficacy and Safety of Relacorilant in Patients With Adrenal Hypercortisolism: Results From a Phase 3 Study

Hamrahian et al. • 2025 • AACE 2025 Congress

May 16, 2025

Characterization of Patients With Difficult-to-Control Type 2 Diabetes and a Post–Dexamethasone Suppression Test Cortisol of 1.2–1.8 μg/dL: Findings From a Large Prospective Study

Busch et al. • 2025 • AACE 2025 Congress

May 15, 2025

A Comprehensive Safety Assessment of Relacorilant: Insights From Phase 2 and Phase 3 Trials in Patients With Endogenous Hypercortisolism

Hannoush et al. • 2025 • AACE 2025 Congress

May 15, 2025

Clinical Learnings Based on a Case Series: Considerations for Identifying and Treating Hypercortisolism in Patients with Diabetes

Lucci et al. • 2025 • AACE

May 15, 2025

Effect of Hepatic Impairment on the Pharmacokinetics of Miricorilant: Results from a Phase 1, Open-Label, Adaptive-Design Study

Custodio et al. • 2025 • EASL 2025 Congress

May 12, 2025

Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study

Pivonello et al. • 2025 • ESPE, ESE

May 10, 2025